Asset Details
Do you wish to reserve the book?
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
Do you wish to request the book?
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Longitudinal changes in KL6 levels predict acute exacerbation in fibrotic interstitial lung disease
2025
Overview
Krebs von den Lungen-6 (KL-6) levels are potentially indicative markers of prospective acute exacerbation (AE) in interstitial lung disease (ILD); however, their longitudinal trends have not been sufficiently investigated. We investigated the predictive ability of patient-specific changes in serum KL-6 levels for predicting AE in patients with fibrotic ILD. We included patients with fibrotic ILDs from the RWD database in Japan who received antifibrotic therapy and had at least two serum KL-6 values during the follow-up. The outcome was AE defined based on primary diagnoses, emergency admission, and pulse/high-dose steroids on the day of or after admission. We used the joint regression model integrating longitudinal and survival analyses to assess the predictive ability of each patient’s serial serum KL-6 measurements for AE. Among 939 patients with fibrotic ILDs, 194 (21%) patients experienced AE during follow-up (event rate, 0.13/person-year; 1-year incidence, 35%). The AE hazard ratio comparing patients with differing cumulative serum KL-6 levels was 1.54 (95% confidence interval: 1.20–1.98,
p
< 0.001). In conclusion, AE in fibrotic ILD patients on antifibrotic therapy may be predicted by high baseline KL-6 levels and their increasing trend. Serial KL-6 monitoring can serve as a valuable tool in a multifaceted approach.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/499
/ Aged
/ Dyspnea
/ Female
/ Fibrotic interstitial lung disease
/ Humanities and Social Sciences
/ Humans
/ Interstitial lung disease exacerbation
/ Japan
/ KL-6
/ Lung Diseases, Interstitial - blood
/ Lung Diseases, Interstitial - diagnosis
/ Lung Diseases, Interstitial - drug therapy
/ Lung Diseases, Interstitial - pathology
/ Male
/ Patients
/ Science
